Immunoprecise Antibodies Ltd
IPA
View Detailed Chart
2.070USD
0.000
Market hours （ET）Quotes delayed by 15 min
95.54MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
0.00%
5 Days
0.00%
1 Month
0.00%
6 Months
+105.97%
Year to Date
+402.79%
1 Year
+417.37%
View Detailed Chart
TradingKey Stock Score of Immunoprecise Antibodies Ltd
Currency: USD Updated: 2025-09-03Key Insights
Immunoprecise Antibodies Ltd's fundamentals are relatively very healthy, Its valuation is considered undervalued, Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at max_target_price.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Immunoprecise Antibodies Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
2
analysts
Buy
Current Rating
4.000
Target Price
+107.25%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Immunoprecise Antibodies Ltd Highlights
StrengthsRisks
ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies. It has several subsidiaries in North America and Europe including entities, such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the IPA Family). Its Contract Research Organizations (CRO) services include B cell Select; Phage Display; DeepDisplay; Abthena Bispecifics; LucinaTech Humanization; Affinity Maturation; Immunization, hybridoma, sequencing; rPEx protein manufacturing, and Cell line development. The Company utilizes custom antigen modeling, target analysis using Natural Language Processing and the HYFTTM analysis to lay the groundwork for the subsequent experimental phases.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 26.62% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 24.52M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 62.65.
Undervalued
The company’s latest PE is -2.29, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 8.16M shares, increasing 14.61% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 40.48K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.32.
Immunoprecise Antibodies Ltd News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Immunoprecise Antibodies Ltd Info
ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies. It has several subsidiaries in North America and Europe including entities, such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the IPA Family). Its Contract Research Organizations (CRO) services include B cell Select; Phage Display; DeepDisplay; Abthena Bispecifics; LucinaTech Humanization; Affinity Maturation; Immunization, hybridoma, sequencing; rPEx protein manufacturing, and Cell line development. The Company utilizes custom antigen modeling, target analysis using Natural Language Processing and the HYFTTM analysis to lay the groundwork for the subsequent experimental phases.
Ticker SymbolIPA
CompanyImmunoprecise Antibodies Ltd
CEODr. Jennifer Lynne Bath, Ph.D.
Websitehttps://www.ipatherapeutics.com/
FAQs
What is the current price of Immunoprecise Antibodies Ltd (IPA)?
The current price of Immunoprecise Antibodies Ltd (IPA) is 2.070.
What is the symbol of Immunoprecise Antibodies Ltd?
The ticker symbol of Immunoprecise Antibodies Ltd is IPA.
What is the 52-week high of Immunoprecise Antibodies Ltd?
The 52-week high of Immunoprecise Antibodies Ltd is 3.246.
What is the 52-week low of Immunoprecise Antibodies Ltd?
The 52-week low of Immunoprecise Antibodies Ltd is 0.270.
What is the market capitalization of Immunoprecise Antibodies Ltd?
The market capitalization of Immunoprecise Antibodies Ltd is 95.54M.
What is the net income of Immunoprecise Antibodies Ltd?
The net income of Immunoprecise Antibodies Ltd is -30.23M.
Is Immunoprecise Antibodies Ltd (IPA) currently rated as Buy, Hold, or Sell?
According to analysts, Immunoprecise Antibodies Ltd (IPA) has an overall rating of Buy, with a price target of 4.000.
What is the Earnings Per Share (EPS TTM) of Immunoprecise Antibodies Ltd (IPA)?
The Earnings Per Share (EPS TTM) of Immunoprecise Antibodies Ltd (IPA) is -0.906.
Related Instruments
+0.71%
+0.37%
-0.54%
-0.08%
+0.38%
+1.14%
+0.57%
-0.84%
-0.17%
+0.54%
-0.46%
+0.17%
+0.17%
-0.23%
+0.34%
+0.51%
+1.03%
0.00%
-0.47%
+1.04%Popular Symbols
